Bryan, Garnier & Co announces the successful €13.2m Euronext IPO of Amoéba
Paris, July 10th, 2015 – Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces the successful €13.2m IPO of Amoéba, producer of a “green” biocide aiming to substitute the chemical biocides for water treatment in industrial environments. Bryan, Garnier & Co acted as Global Coordinator and Joint Bookrunner, strengthening its leadership position in the Cleantech & Renewables sector.
Amoéba, a producer of “green” Biocide aiming to substitute the chemical biocides currently used in industrial water treatment, has successfully completed its IPO on Euronext Paris. Bryan, Garnier & Co acted as Global Coordinator and Joint Bookrunner for this IPO. The transaction was oversubscribed with over 40 institutional investors.
The final offer price was set at €8.30 per share resulting in a market capitalization at IPO of approximately €44,5 million. Amoéba will issue 1,592,307 new shares including the fully exercised extension option (207,692 shares). 81% of the placement was subscribed by institutional investors and 19% by retail investors.
With strong patents and demonstrated production scalability, Amoéba is ideally positioned to substitute chemical biocides in industrial water treatment. The proceeds from the IPO will finance the industrial rollout and commercial developments of Amoéba in Europe and North America.
Olivier Beaudouin, Partner leading the Cleantech franchise commented : “Our deep knowledge of the Cleantech and Biotech sectors have enabled us to identify early on Amoéba as a unique company at the crossroads between those two sectors. The company’s operational milestones, low capex technology and non-disruptive implementation with industrial clients have been decisive factors to convince investors in challenging market conditions due to the recent Greek events. Following the €32m IPO of McPhy and €115m capital increase for Voltalia, Bryan Garnier & Co confirms its leading position as an advisor to Cleantech companies on European capital markets”.
For more information, please contact:
Olivier Beaudouin
Partner –Corporate Finance – Technology & Cleantech
obeaudouin@bryangarnier.com | + 33 1 56 68 75 35
Christian Finan
Director – Equity Capital Markets
cfinan@bryangarnier.com | + 33 156687530
Marc Goudemand
Principal – Corporate Finance
mgoudemand@bryangarnier.com | + 33 170365715
About Amoéba (www.amoeba-biocide.com)
Created in 2010 after acquiring the exclusive licence from the Claude Bernard University in Lyon (UCLB) to use and exploit the natural biocide properties of the Willaertia magna amoeba, Amoéba develops and is set to market (as of 2016 for the French market) a biological biocide that is harmless for man and the environment, and capable of reducing by 99.5% the presence of pathogenic bacteria such as Legionella, Listeria and Pseudomonas which are present in industrial waters.
About Bryan, Garnier & Co (www.bryangarnier.com)
Bryan, Garnier & Co is an international growth-focused independent investment bank with operations in London, Paris, Geneva, New York and New Delhi. Since 1996, Bryan, Garnier & Co has dealt with over 300 corporate clients. The firm employs 120 people and provides equity research, sales & trading, private and public capital raising and M&A services to growth companies and their investors, with a focus on the TMT, Healthcare, Renewable Energies & Environment, Specialty Retail and Business Services industry sectors. In 2013, Bryan, Garnier & Co received the Most Productive European Broker Award by Financial Times / Starmine. Bryan, Garnier & Co is a fully registered broker dealer authorized by the FCA in Europe and by the FINRA in the USA, and is a member of the London Stock Exchange, a member of NYSE Euronext and a listing sponsor on Alternext.